NTRA 9620

Drug Profile

NTRA 9620

Alternative Names: NTRA-9620

Latest Information Update: 24 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nutrinia
  • Class Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Short bowel syndrome

Most Recent Events

  • 26 Aug 2016 Nutrinia plans a phase II/III trial in Short bowel syndrome (In infants) in USA and European Union , NCT02865122)
  • 18 Aug 2016 Nutrinia plans a clinical trial for Malbsorption disorders in USA and European Union
  • 15 Jun 2015 NTRA 9620 receives Orphan Drug status for Short bowel syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top